The company said it recorded net income of $169.5 million, basic net income per share of $0.76 and diluted net income per share of $0.75 for the 3 months ended March 31, 2024. For the same period in 2023, net income was $21.7 million, and basic and diluted net income per share were $0.10 each.

1. 01

   The company said it recorded net income of $169.5 million, basic net income per share of $0.76 and diluted net income per share of $0.75 for the 3 months ended March 31, 2024. For the same period in 2023, net income was $21.7 million, and basic and diluted net income per share were $0.10 each.

2. 02

   Incyte said the decline in JAKAFI net product revenues consisted of a volume decrease of $17.8 million and a price increase of $9.6 million. The company cited a decrease in channel inventory as the main factor behind the decline.

3. 03

   The company said it sued the U.S. Centers for Medicare and Medicaid Services (CMS), alleging that its line extension definition rule treats OPZELURA as a line extension of JAKAFI. As of March 31, 2024, it had accrued approximately $73.7 million in accrued and other current liabilities for the related incremental rebates.

4. 04

   As of March 31, 2024, the company said it had cash, cash equivalents and marketable securities of $3.9 billion, and net cash provided by operating activities was $218.8 million for the 3 months. It cited changes in working capital as the factor behind the increase in operating cash flow. The company also said it had no borrowings outstanding under the $500.0 million revolving credit facility as of the same date.

Key figures

Quarter ended March 31, 2024

Revenue

$881M

Operating income

$92M

Net income

$170M

EPS

$0.75

Operating cash flow

$219M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.